Sacubitril/Allisartan Versus Amlodipine for Hypertensive Patients With Overweight or Obesity: A Multicenter, Open-Label, Randomized Controlled Trial (SHOT)

NCT07241338 Phase 4 NOT_YET_RECRUITING

To compare the efficacy and safety of sacubitril/Allisartan versus amlodipine in the antihypertensive treatment of overweight/obese patients with primary hypertension

Details

Lead sponsor	Jing Liu
Phase	Phase 4
Status	NOT_YET_RECRUITING
Enrolment	104
Start date	2025-11
Completion	2027-06

Conditions

• Hypertension

Interventions

• sacubitril/allisartan
• Amlodipine

Primary outcomes

• The change in the mean sitting systolic blood pressure (msSBP) from baseline to week 8, assessed for sacubitril/allisartan as compared to amlodipine — From the start of randomization to the end of treatment at 8 weeks

Countries

China